February 1st, 2013
Your Blog, Your CV, and Academic Promotion
Shengshou Hu, M.D.
Is it time for academic centers to include social media contributions as part of their academic promotion criteria?
January 30th, 2013
How Insurance Status Affects Treatment for Patients with CAD
Kim G. Smolderen, PhD, Paul S. Chan, MD, MS and John Ryan, MD
Does a patient’s insurance status affect a physician’s decision to prescribe evidence-based therapies for CAD?
January 29th, 2013
FDA Approves Mipomersen for Homozygous Familial Hypercholesterolemia
Larry Husten, PHD
The FDA said today that it had granted approval to the novel cholesterol-lowering drug mipomersen sodium for use as an adjunct to diet and drug therapy in patients with homozygous hypercholesterolemia. The drug, which was developed by Isis Pharmaceuticals, will be marketed under the brand name of Kynamro by Genzyme. Kynamro was approved as an orphan drug, which […]
January 29th, 2013
Popular Antidepressants May Prolong QT Interval
Larry Husten, PHD
In August 2011 the FDA issued a safety communication recommending that the extremely popular antidepressant citalopram (Celexa) not be used at doses greater than 40 mg/day because of a potential increased risk for serious cardiac arrhythmias associated with prolongation of the QT interval. Now a study published in BMJ lends support to this warning and suggests that other antidepressants may […]
January 29th, 2013
Selections from Richard Lehman’s Literature Review: January 28th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include using hospital readmission as a quality marker and the cardiovascular safety of peginesatide for anemia in patients with CKD.
January 29th, 2013
In REGARDS to Depression, MI, and Death in Patients with CHD
monikasafford393
Monika Safford discusses the behavioral mechanisms that most contribute to the association between depression and MI or death in those with CHD.
January 28th, 2013
Study Warns Against Dual Blockade of Renin-Angiotensin System in Heart Failure and Hypertension
Larry Husten, PHD
The enormous success of ACE inhibitors in hypertension and heart failure spurred hope that adding a second drug to block the renin-angiotensin system would yield improved outcomes. Although definitive evidence supporting dual blockade of the renin-angiotensin system has never been found, more than 200,000 patients in the U.S. currently receive this therapy. Now a large new meta-analysis […]
January 28th, 2013
Getting a Read on St. Jude Leads: An Interview with Robert G. Hauser
Robert George Hauser, BS MD and John Ryan, MD
The researcher and EP who first documented problems with St. Jude next generation leads reacts to the FDA’s recent letter to the company and explains what he is doing for patients who have received these devices.
January 25th, 2013
Appropriate Use or Defensive Medicine?
Sarah C. Hull, MD, MBE (Master of Bioethics)
Is the practice of defensive medicine overriding the implementation of appropriate use to the detriment of economics, patient care, and medical education?
January 24th, 2013
Hospital Readmissions May Be Just the Tip of the Iceberg
Anita Vashi, MD, MPH
Do you know when your patients end up back in the ED but are not rehospitalized?
NEJM — Recent Cardiology Articles- Medicare’s Role in Fighting Chronic Disease January 24, 2026The U.S. government can combat chronic disease among Medicare patients by strengthening primary care, expanding access to preventive care, making care more affordable, and modernizing Medicare benefits.
- The Hypertension Control Paradox — Why Is America Stuck? January 24, 2026Why is the United States failing to control the population’s blood pressure, despite the availability of well-understood, effective interventions? And what can health systems do to move the needle?
- Anticoagulation after Ablation for Atrial Fibrillation — Navigating the OCEAN of Possibilities January 22, 2026Under current guidelines, discontinuation of oral anticoagulant therapy is not considered to be a benefit that can be routinely offered to patients who have undergone ablation for atrial fibrillation. Even after apparently successful ablation, continuation of anticoagulant therapy is recommended when indicated by the CHA2DS2 -VASc score...
- Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Autonomy vs. Equity — NOS Episode 3.9 January 22, 2026With increasing numbers of PCPs leaving traditional practice for concierge medicine or direct primary care, NOS host Lisa Rosenbaum and her guests explore the promise and perils.
- Physiologic Pacing in Heart Failure January 22, 2026This review summarizes cardiac physiologic pacing for heart failure, highlighting benefits of biventricular pacing and emerging evidence for His-bundle and left bundle-branch pacing to improve function and outcomes.
- Medicare’s Role in Fighting Chronic Disease January 24, 2026